Compare FGBI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | AGEN |
|---|---|---|
| Founded | 1934 | 1994 |
| Country | United States | United States |
| Employees | 346 | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 147.4M |
| IPO Year | N/A | 1999 |
| Metric | FGBI | AGEN |
|---|---|---|
| Price | $9.91 | $6.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 67.7K | ★ 906.5K |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $567.70 | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.28 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $4.31 | $2.71 |
| 52 Week High | $11.02 | $7.00 |
| Indicator | FGBI | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 83.67 |
| Support Level | $9.42 | $2.96 |
| Resistance Level | $10.03 | N/A |
| Average True Range (ATR) | 0.55 | 0.49 |
| MACD | -0.08 | 0.22 |
| Stochastic Oscillator | 25.88 | 58.29 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.